Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver.

Sanoh S, Tamura Y, Fujino C, Sugahara G, Yoshizane Y, Yanagi A, Kisoh K, Ishida Y, Tateno C, Ohta S, Kotake Y.

Biol Pharm Bull. 2019;42(8):1366-1375. doi: 10.1248/bpb.b19-00249.

2.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

PMID:
31199224
3.

Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP.

Makokha GN, Abe-Chayama H, Chowdhury S, Hayes CN, Tsuge M, Yoshima T, Ishida Y, Zhang Y, Uchida T, Tateno C, Akiyama R, Chayama K.

Sci Rep. 2019 Jun 11;9(1):8462. doi: 10.1038/s41598-019-44934-5.

4.

Coordinated cytochrome P450 expression in mouse liver and intestine under different dietary conditions during liver regeneration after partial hepatectomy.

Fujino C, Sanoh S, Tateno C, Ohta S, Kotake Y.

Toxicol Appl Pharmacol. 2019 May 1;370:133-144. doi: 10.1016/j.taap.2019.03.010. Epub 2019 Mar 14.

PMID:
30880217
5.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

6.

Prediction of Human Hepatic Clearance for Cytochrome P450 Substrates via a New Culture Method Using the Collagen Vitrigel Membrane Chamber and Fresh Hepatocytes Isolated from Liver Humanized Mice.

Watari R, Kakiki M, Yamasaki C, Ishida Y, Tateno C, Kuroda Y, Ishida S, Kusano K.

Biol Pharm Bull. 2019;42(3):348-353. doi: 10.1248/bpb.b18-00582.

7.

Chimeric mice with human hepatocytes: A new system for genotoxicity studies.

Tateno C, Fukumuro M, Masumori S, Kakuni M, Ishida Y, Shimada T, Hayashi M.

Mutat Res Genet Toxicol Environ Mutagen. 2019 Mar;839:9-12. doi: 10.1016/j.mrgentox.2019.01.003. Epub 2019 Jan 14.

PMID:
30744813
8.

Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver.

Harimoto N, Nakagawara H, Shirabe K, Yoshizumi T, Itoh S, Ikegami T, Soejima Y, Maehara Y, Ishida Y, Tateno C, Tanaka Y.

Transplant Proc. 2018 Dec;50(10):3858-3862. doi: 10.1016/j.transproceed.2018.06.035. Epub 2018 Jun 30.

PMID:
30577278
9.

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model.

Ye X, Tateno C, Thi EP, Kakuni M, Snead NM, Ishida Y, Barnard TR, Sofia MJ, Shimada T, Lee ACH.

ACS Infect Dis. 2019 May 10;5(5):738-749. doi: 10.1021/acsinfecdis.8b00192. Epub 2018 Nov 20.

PMID:
30408957
10.

A long-term culture system based on a collagen vitrigel membrane chamber that supports liver-specific functions of hepatocytes isolated from mice with humanized livers.

Watari R, Kakiki M, Oshikata A, Takezawa T, Yamasaki C, Ishida Y, Tateno C, Kuroda Y, Ishida S, Kusano K.

J Toxicol Sci. 2018;43(8):521-529. doi: 10.2131/jts.43.521.

11.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2018 Aug;99(8):1058-1065. doi: 10.1099/jgv.0.001091. Epub 2018 Jun 19.

PMID:
29916799
12.

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice.

de la Rosa Rodriguez MA, Sugahara G, Hooiveld GJEJ, Ishida Y, Tateno C, Kersten S.

BMC Genomics. 2018 Jun 7;19(1):443. doi: 10.1186/s12864-018-4834-3.

13.

Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions.

Takaoka N, Sanoh S, Okuda K, Kotake Y, Sugahara G, Yanagi A, Ishida Y, Tateno C, Tayama Y, Sugihara K, Kitamura S, Kurosaki M, Terao M, Garattini E, Ohta S.

Biochem Pharmacol. 2018 Aug;154:28-38. doi: 10.1016/j.bcp.2018.04.017. Epub 2018 Apr 17.

PMID:
29678521
14.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.

Teraoka Y, Uchida T, Imamura M, Osawa M, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K; Hiroshima Liver Study Group.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157. doi: 10.1016/j.bbrc.2018.04.005. Epub 2018 Apr 13.

PMID:
29621544
15.

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K.

Hepatology. 2018 Aug;68(2):473-484. doi: 10.1002/hep.29891. Epub 2018 Jun 6.

16.

Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver.

Uchida M, Tajima Y, Kakuni M, Kageyama Y, Okada T, Sakurada E, Tateno C, Hayashi R.

Drug Metab Dispos. 2018 Jan;46(1):11-19. doi: 10.1124/dmd.117.075994. Epub 2017 Oct 19.

PMID:
29051147
17.

Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver.

Sanoh S, Yamachika Y, Tamura Y, Kotake Y, Yoshizane Y, Ishida Y, Tateno C, Ohta S.

J Toxicol Sci. 2017;42(5):589-596. doi: 10.2131/jts.42.589.

18.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00725-17. doi: 10.1128/AAC.00725-17. Print 2017 Sep.

19.

Transmission of HBV DNA Mediated by Ceramide-Triggered Extracellular Vesicles.

Sanada T, Hirata Y, Naito Y, Yamamoto N, Kikkawa Y, Ishida Y, Yamasaki C, Tateno C, Ochiya T, Kohara M.

Cell Mol Gastroenterol Hepatol. 2016 Oct 24;3(2):272-283. doi: 10.1016/j.jcmgh.2016.10.003. eCollection 2017 Mar.

20.

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.

Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Serikawa M, Aikata H, Ochi H, Ishida Y, Tateno C, Ohdan H, Chayama K.

PLoS One. 2017 Mar 2;12(3):e0172412. doi: 10.1371/journal.pone.0172412. eCollection 2017.

21.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.

Uchida T, Imamura M, Kan H, Hiraga N, Hayes CN, Tsuge M, Abe-Chayama H, Aikata H, Makokha GN, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2017 May;98(5):1040-1047. doi: 10.1099/jgv.0.000726. Epub 2017 May 25.

PMID:
28141486
22.
23.

Corrigendum to 'Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus' [Virology (2014) 157-168].

Yasui F, Kohara M, Kitabatake M, Nishiwaki T, Fujii H, Tateno C, Yoneda M, Morita K, Matsushima K, Koyasu S, Kai C.

Virology. 2016 Dec;499:397-398. doi: 10.1016/j.virol.2016.10.018. No abstract available.

24.

Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.

Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN, Tsuge M, Abe H, Aikata H, Makokha GN, Chowdhury S, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Infect Dis. 2016 Dec 1;214(11):1687-1694. Epub 2016 Sep 20.

PMID:
27651415
25.

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

DebRoy S, Hiraga N, Imamura M, Hayes CN, Akamatsu S, Canini L, Perelson AS, Pohl RT, Persiani S, Uprichard SL, Tateno C, Dahari H, Chayama K.

J Viral Hepat. 2016 Sep;23(9):708-17. doi: 10.1111/jvh.12551. Epub 2016 Jun 8.

26.

Development of the Heart Endocardium at an Early Stage of Chick Embryos Evaluated at Light- and Electron-Microscopic Levels.

Hara Y, Wake K, Inoue K, Kuroda N, Sato A, Inamatsu M, Tateno C, Sato T.

Anat Rec (Hoboken). 2016 Aug;299(8):1080-9. doi: 10.1002/ar.23372. Epub 2016 Jun 1.

27.

[In vivo and in vitro HBV infection model using chimeric mice with humanized livers].

Ishida Y, Yokomichi H, Kakuni M, Tateno C.

Nihon Rinsho. 2015 Dec;73 Suppl 9:386-91. Japanese. No abstract available.

PMID:
26845964
28.

Property of hepatitis B virus replication in Tupaia belangeri hepatocytes.

Sanada T, Tsukiyama-Kohara K, Yamamoto N, Ezzikouri S, Benjelloun S, Murakami S, Tanaka Y, Tateno C, Kohara M.

Biochem Biophys Res Commun. 2016 Jan 8;469(2):229-35. doi: 10.1016/j.bbrc.2015.11.121. Epub 2015 Nov 30.

29.

Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.

Uchida T, Hiraga N, Imamura M, Yoshimi S, Kan H, Miyaki E, Tsuge M, Abe H, Hayes CN, Aikata H, Ishida Y, Tateno C, Ellis JD, Chayama K.

Virus Res. 2016 Feb 2;213:62-68. doi: 10.1016/j.virusres.2015.11.010. Epub 2015 Nov 10.

PMID:
26569595
30.

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.

Kan H, Hiraga N, Imamura M, Hayes CN, Uchida T, Miyaki E, Tsuge M, Abe H, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antivir Ther. 2016;21(4):307-15. doi: 10.3851/IMP3009. Epub 2015 Nov 12.

PMID:
26562322
31.

Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice.

Tateno C, Kawase Y, Tobita Y, Hamamura S, Ohshita H, Yokomichi H, Sanada H, Kakuni M, Shiota A, Kojima Y, Ishida Y, Shitara H, Wada NA, Tateishi H, Sudoh M, Nagatsuka S, Jishage K, Kohara M.

PLoS One. 2015 Nov 4;10(11):e0142145. doi: 10.1371/journal.pone.0142145. eCollection 2015.

32.

Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.

Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, Hirata Y, Murakami S, Tanaka Y, Chayama K, Hatakeyama H, Hyodo M, Harashima H, Kohara M.

J Hepatol. 2016 Mar;64(3):547-55. doi: 10.1016/j.jhep.2015.10.014. Epub 2015 Oct 24.

33.

M2 Macrophages Play Critical Roles in Progression of Inflammatory Liver Disease in Hepatitis C Virus Transgenic Mice.

Ohtsuki T, Kimura K, Tokunaga Y, Tsukiyama-Kohara K, Tateno C, Hayashi Y, Hishima T, Kohara M.

J Virol. 2015 Oct 14;90(1):300-7. doi: 10.1128/JVI.02293-15. Print 2016 Jan 1.

34.

Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.

Nakada N, Kawamura A, Kamimura H, Sato K, Kazuki Y, Kakuni M, Ohbuchi M, Kato K, Tateno C, Oshimura M, Usui T.

Biopharm Drug Dispos. 2016 Jan;37(1):3-14. doi: 10.1002/bdd.1990.

PMID:
26352195
35.

Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice.

Uchida T, Hiraga N, Imamura M, Tsuge M, Abe H, Hayes CN, Aikata H, Ishida Y, Tateno C, Yoshizato K, Ohdan H, Murakami K, Chayama K.

J Virol. 2015 Oct;89(19):10087-96. doi: 10.1128/JVI.01126-15. Epub 2015 Aug 5.

36.

Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver.

Kato K, Ohbuchi M, Hamamura S, Ohshita H, Kazuki Y, Oshimura M, Sato K, Nakada N, Kawamura A, Usui T, Kamimura H, Tateno C.

Drug Metab Dispos. 2015 Aug;43(8):1208-17. doi: 10.1124/dmd.115.063479. Epub 2015 May 15.

PMID:
25979261
37.

Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice.

Ishida Y, Yamasaki C, Yanagi A, Yoshizane Y, Fujikawa K, Watashi K, Abe H, Wakita T, Hayes CN, Chayama K, Tateno C.

Am J Pathol. 2015 May;185(5):1275-85. doi: 10.1016/j.ajpath.2015.01.028. Epub 2015 Mar 17.

PMID:
25791527
38.

Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver.

Sanoh S, Naritomi Y, Fujimoto M, Sato K, Kawamura A, Horiguchi A, Sugihara K, Kotake Y, Ohshita H, Tateno C, Horie T, Kitamura S, Ohta S.

Xenobiotica. 2015;45(7):605-14. doi: 10.3109/00498254.2015.1007112. Epub 2015 Mar 3.

PMID:
25733030
39.

Enhanced restoration of in situ-damaged hairs by intradermal transplantation of trichogenous dermal cells.

Yamao M, Inamatsu M, Okada T, Ogawa Y, Tateno C, Yoshizato K.

J Tissue Eng Regen Med. 2017 Apr;11(4):977-988. doi: 10.1002/term.1997. Epub 2015 Feb 17.

PMID:
25689375
40.

Restorative effect of hair follicular dermal cells on injured human hair follicles in a mouse model.

Yamao M, Inamatsu M, Okada T, Ogawa Y, Ishida Y, Tateno C, Yoshizato K.

Exp Dermatol. 2015 Mar;24(3):225-7. doi: 10.1111/exd.12625.

PMID:
25557326
41.

Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-α.

Tateno C, Yamamoto T, Utoh R, Yamasaki C, Ishida Y, Myoken Y, Oofusa K, Okada M, Tsutsui N, Yoshizato K.

Toxicol Pathol. 2015 Feb;43(2):233-48. doi: 10.1177/0192623314544378. Epub 2014 Aug 8.

PMID:
25107573
42.

Efficient Engraftment of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells in uPA/SCID Mice by Overexpression of FNK, a Bcl-xL Mutant Gene.

Nagamoto Y, Takayama K, Tashiro K, Tateno C, Sakurai F, Tachibana M, Kawabata K, Ikeda K, Tanaka Y, Mizuguchi H.

Cell Transplant. 2015;24(6):1127-38. doi: 10.3727/096368914X681702. Epub 2014 May 6.

PMID:
24806294
43.

Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus.

Yasui F, Kohara M, Kitabatake M, Nishiwaki T, Fujii H, Tateno C, Yoneda M, Morita K, Matsushima K, Koyasu S, Kai C.

Virology. 2014 Apr;454-455:157-68. doi: 10.1016/j.virol.2014.02.005. Epub 2014 Mar 4. Erratum in: Virology. 2016 Dec;499:397-398.

44.

Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS.

Ohtsuki S, Kawakami H, Inoue T, Nakamura K, Tateno C, Katsukura Y, Obuchi W, Uchida Y, Kamiie J, Horie T, Terasaki T.

Drug Metab Dispos. 2014 Jun;42(6):1039-43. doi: 10.1124/dmd.114.057646. Epub 2014 Apr 7.

PMID:
24711249
45.

Chimeric mice with humanized livers: a unique tool for in vivo and in vitro enzyme induction studies.

Kakuni M, Yamasaki C, Tachibana A, Yoshizane Y, Ishida Y, Tateno C.

Int J Mol Sci. 2013 Dec 20;15(1):58-74. doi: 10.3390/ijms15010058.

46.

Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain HCV-RMT.

Arai M, Tokunaga Y, Takagi A, Tobita Y, Hirata Y, Ishida Y, Tateno C, Kohara M.

PLoS One. 2013 Dec 16;8(12):e82527. doi: 10.1371/journal.pone.0082527. eCollection 2013.

47.

A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.

Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T, Chayama K.

Biochem Biophys Res Commun. 2013 Nov 8;441(1):230-5. doi: 10.1016/j.bbrc.2013.10.040. Epub 2013 Oct 16.

PMID:
24140055
48.

A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next?

Yoshizato K, Tateno C.

Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1419-35. doi: 10.1517/17425255.2013.826649. Epub 2013 Aug 27. Review.

PMID:
23978259
49.

Repopulation of the immunosuppressed retrorsine-treated infant rat liver with human hepatocytes.

Tachibana A, Tateno C, Yoshizato K.

Xenotransplantation. 2013 Jul-Aug;20(4):227-38. doi: 10.1111/xen.12037. Epub 2013 May 20.

PMID:
23683097
50.

Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection.

Nakagawa S, Hirata Y, Kameyama T, Tokunaga Y, Nishito Y, Hirabayashi K, Yano J, Ochiya T, Tateno C, Tanaka Y, Mizokami M, Tsukiyama-Kohara K, Inoue K, Yoshiba M, Takaoka A, Kohara M.

PLoS One. 2013;8(3):e59611. doi: 10.1371/journal.pone.0059611. Epub 2013 Mar 28.

Supplemental Content

Loading ...
Support Center